Moderate Uterine Fibroids

Also known as: Moderate Uterine fibroid

Drug	Drug Name	Drug Description
DB17083	Linzagolix	A selective gonadotropin-releasing hormone (GnRH) receptor antagonist used for the symptomatic treatment of uterine fibroids.
DB08867	Ulipristal	A selective progesterone receptor modulator used for emergency contraception after unprotected intercourse or in a situation where a planned method of contraception has failed.

Drug	Drug Name	Target	Type
DB17083	Linzagolix	Cytochrome P450 2C8	enzyme
DB17083	Linzagolix	Gonadotropin-releasing hormone receptor	target
DB17083	Linzagolix	Serum albumin	carrier
DB17083	Linzagolix	Cytochrome P450 2C9	enzyme
DB17083	Linzagolix	Cytochrome P450 3A4	enzyme
DB17083	Linzagolix	Solute carrier organic anion transporter family member 1B1	transporter
DB17083	Linzagolix	Solute carrier organic anion transporter family member 1B3	transporter
DB17083	Linzagolix	Solute carrier family 22 member 8	transporter
DB17083	Linzagolix	ATP-binding cassette sub-family G member 2	transporter
DB17083	Linzagolix	Solute carrier family 22 member 6	transporter
DB08867	Ulipristal	Progesterone receptor	target
DB08867	Ulipristal	Glucocorticoid receptor	target
DB08867	Ulipristal	Androgen receptor	target
DB08867	Ulipristal	Cytochrome P450 3A4	enzyme
DB08867	Ulipristal	Cytochrome P450 1A2	enzyme
DB08867	Ulipristal	Serum albumin	carrier
DB08867	Ulipristal	Alpha-1-acid glycoprotein 1	carrier

Drug	Drug Name	Phase	Status	Count